Scope of the guidance
The FDA's November 2 announcement introduces final guidance on potency assurance for cellular and gene therapy products. It replaces the agency's 2011 potency-testing guidance and describes a strategy extending from early development into commercial production.
The document addresses material controls, manufacturing design and control, tests during production and assays before batch release. It includes considerations for short-lived products, viral vectors and therapies made for individual patients. A Federal Register notice followed on November 3. This is a quality framework, not approval of a new treatment or evidence of a particular clinical benefit.
Implementation to follow
For a developer, the practical issue is how a potency result informs a decision while it can still be acted on. A slow assay can complicate release of a short-lived product. A patient-specific therapy requires an evidence strategy suited to its production run.
The FDA has scheduled a December 10 webinar. I would look for implementation examples connecting manufacturing controls, assay results and release decisions. Announced capacity alone leaves those connections unresolved. Access claims also require evidence about cost, payment and treatment-centre capacity beyond this guidance.
Sources & methods
FDA — Cell and gene therapy development and quality announcementPublished Nov 2, 2026FDA — Final potency assurance guidanceFederal Register — Notice of final guidance availabilityPublished Nov 3, 2026Updated Nov 5, 2026. Editorial standards.
